New Research Confirms Value of Multimodal Treatment for Mesothelioma, According to Surviving Mesothelioma

Share Article

Doctors say a combination treatment plan including surgery, pleural lavage, radiotherapy and chemotherapy may give pleural mesothelioma patients their best odds for survival.

Study Supports Multimodal Mesothelioma Treatment

Multimodal Treatment for Mesothelioma

Median survival and 5-year survival rates were 35.0 months and 30.7% for epithelioid mesothelioma ...

A new study of more than a hundred mesothelioma surgery patients finds that those who had a pleural antiseptic rinse, radiation, and chemotherapy (either before or after surgery) had a median survival of more than 2-and-a-half years. Click here to read more on the new research on the Surviving Mesothelioma website.

Scientific investigators at two London hospitals and the University of Milan have just published their encouraging survival statistics on patients who underwent multimodal treatment for mesothelioma, one of the rarest but most aggressive cancers.

“Median survival and 5-year survival rates were 35.0 months and 30.7% for epithelioid mesothelioma and 15 months and 7% for nonepithelioid mesothelioma, respectively,” reports lead author Dr. Loic Lang-Lazdunski, a thoracic surgeon in the Division of Cancer Studies at London’s Kings College.

The prognosis for pleural mesothelioma is usually grim with most patients succumbing to the disease within a year of diagnosis. But the new report, published in the Journal of Thoracic and Cardiovascular Surgery, found that some patients on combination therapy lived five years or more.

“These statistics reinforce the idea that there is no one treatment that is best for mesothelioma,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “Successful mesothelioma treatment almost always depends on a strategic combination of therapies.”

To read more on the combination that proved so successful in the new study, see Mesothelioma Patients Live Longer with Multimodal Treatment, now available on the Surviving Mesothelioma website.

Lang-Lazdunski, L, “Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience.” February 2015, Journal of Thoracic and Cardiovascular Surgery, pp. 558-566.

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website